Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cetuximab study in TERT promoter-mutant oral cavity cancer after failure of platinum chemotherapy and/or immune checkpoint inhibitors
KCT0011650Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in mouth cancer, sponsored by Merck & Co.. Started Sep 2026; status: recruiting.
02
Drugs
cetuximab
03
Conditions
mouth cancer
Beyond the preview
Go deeper on KCT0011650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011650.